Evidence map›Paper›PMID 27493132›Full record

Trial reportDiabetes care2016

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.

Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen and 2 more

3 registry-linked trialsOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetes care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02098395. Cited by 131 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 11 pooled it
12.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02098395 phase3completed

A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial

Ran2014Enrolled835Registered outcomes3Posted comparisons3ConditionsDiabetes, Diabetes Mellitus, Type 1Armsliraglutide, Placebo
PMID 27493232other papers from this trial
Open the trial in the graph
NCT05478707 phase2recruitingstarted 2023, after this paper: background citation

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

Ran2023Enrolled47Registered outcomes5Posted comparisons0ConditionsDiabetes Mellitus, Type 1, Endothelial DysfunctionArmsDulaglutide, Placebo
PMID 29310645PMID 24742660PMID 22732108PMID 27295427PMID 27436611PMID 27633186PMID 28817231PMID 28386795PMID 27506222PMID 27039125PMID 26936306PMID 26739816other papers from this trial
Open the trial in the graph
NCT06894784 phase3recruitingstarted 2025, after this paper: background citation

Semaglutide And Empagliflozin Combination Therapy Added To Automated Insulin Delivery In Adults With Type 1 Diabetes (SEMPA)

Ran2025Enrolled36Registered outcomes13Posted comparisons0ConditionsDiabetes Type 1ArmsIntervention Period 1: Semaglutide + Empagliflozin, Intervention Period 2: Semaglutide + Empagliflozin Placebo, Intervention Period 3: Semaglutide Placebo + Empagliflozin, Intervention Period 4: Semaglutide Placebo + Empagliflozin Placebo
PMID 20616619PMID 36942888PMID 31539622PMID 29246950PMID 27295427PMID 28854085PMID 25388240PMID 24947583PMID 27633186PMID 30833170PMID 29397376PMID 19925391other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 11 syntheses or guidelines pooled it, 236 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 7 countries.

Bo AhrénLund University, Lund, Sweden bo.ahren@med.lu.se.
Irl B HirschUniversity of Washington, Seattle, WA.
Thomas R PieberMedical University of Graz, Graz, Austria.
Chantal MathieuUniversity of Leuven, Leuven, Belgium.
Fernando Gómez-PeraltaHospital General de Segovia, Segovia, Spain.
Troels Krarup HansenAarhus University Hospital, Aarhus, Denmark.
Areti PhilotheouUniversity of Cape Town Private Academic Hospital, Cape Town, South Africa.
Sune BirchNovo Nordisk A/S, Bagsvaerd, Denmark.
Erik ChristiansenNovo Nordisk A/S, Bagsvaerd, Denmark.
Thomas Jon JensenNovo Nordisk A/S, Bagsvaerd, Denmark.
John B BuseUniversity of North Carolina School of Medicine, Chapel Hill, NC.
ADJUNCT TWO Investigators
Novo Nordisk (Denmark) · DKAarhus University Hospital · DKHospital General De Segovia · ESKU Leuven · BELund University · SEMedical University of Graz · ATUniversity of Cape Town · ZAUniversity of North Carolina at Chapel Hill · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the efficacy and safety of liraglutide added to capped insulin doses in subjects with type 1 diabetes. RESEARCH DESIGN AND

methodsA 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of insulin.

resultsMean baseline glycated hemoglobin (HbA1c) (8.1% [65.0 mmol/mol]) was significantly decreased with liraglutide versus placebo at week 26 (1.8 mg: -0.33% [3.6 mmol/mol]; 1.2 mg: -0.22% [2.4 mmol/mol]; 0.6 mg: -0.23% [2.5 mmol/mol]; placebo: 0.01% [0.1 mmol/mol]). Liraglutide significantly reduced mean body weight (-5.1, -4.0, and -2.5 kg for 1.8, 1.2, and 0.6 mg, respectively) versus placebo (-0.2 kg). Significant reductions in daily insulin dose and increases in quality of life were seen with liraglutide versus placebo. There were higher rates of symptomatic hypoglycemia (21.3 vs. 16.6 events/patient/year; P = 0.03) with liraglutide 1.2 mg vs. placebo and of hyperglycemia with ketosis >1.5 mmol/L with liraglutide 1.8 mg vs. placebo (0.5 vs. 0.1 events/patient/year; P = 0.01).

conclusionsIn a broad population of subjects with long-standing type 1 diabetes, liraglutide added to capped insulin reduced HbA1c, body weight, and insulin requirements but with higher rates of hypoglycemia for liraglutide 1.2 mg and hyperglycemia with ketosis for liraglutide 1.8 mg.

Indexed as

AdolescentAdultAgedAged, 80 and overDiabetes Mellitus, Type 1Double-Blind MethodDrug Therapy, CombinationFemaleGlycated HemoglobinHumansHypoglycemic AgentsInjections, SubcutaneousInsulinLiraglutideMaleMiddle AgedGlycated HemoglobinHypoglycemic AgentsInsulinLiraglutide

Identifiers

PMID27493132
OpenAlexW2494601841

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.